| [1] |
|
| [2] |
ZHENG H, WANG Y, WANG FZ, et al. New progress in HBV control and the cascade of health care for people living with HBV in China: Evidence from the fourth national serological survey, 2020[J]. Lancet Reg Health West Pac, 2024, 51: 101193. DOI: 10.1016/j.lanwpc.2024.101193. |
| [3] |
XU XQ, WANG H, SHAN S, et al. Ten-year changes in clinical characteristics and antiviral treatment patterns of chronic hepatitis B in China: A CR-HepB-based real-world study[J]. Chin J Hepatol, 2023, 31( 7): 698- 704. DOI: 10.3760/cma.j.cn501113-20230518-00226. |
| [4] |
MENG TT, MIAO N, ZHENG H, et al. Self-awareness rate and its influencing factors of their infection status among hepatitis B surface antigen-positive persons aged 15-69 years in China[J]. Chin J Hepatol, 2022, 30( 5): 534- 540. DOI: 10.3760/cma.j.cn501113-20220303-00097. |
| [5] |
COOKE GS, FLOWER B, CUNNINGHAM E, et al. Progress towards elimination of viral hepatitis: A lancet gastroenterology& hepatology commission update[J]. Lancet Gastroenterol Hepatol, 2024, 9( 4): 346- 365. DOI: 10.1016/S2468-1253(23)00321-7. |
| [6] |
WANG XR, DU ZC, WANG YJ, et al. Impact and cost-effectiveness of biomedical interventions on adult hepatitis B elimination in China: A mathematical modelling study[J]. J Epidemiol Glob Health, 2023, 13( 3): 517- 527. DOI: 10.1007/s44197-023-00132-1. |
| [7] |
TOY M, HUTTON D, JIA JD, et al. Costs and health impact of delayed implementation of a national hepatitis B treatment program in China[J]. J Glob Health, 2022, 12: 04043. DOI: 10.7189/jogh.12.04043. |
| [8] |
SUN YM, ZHOU JL, WANG L, et al. New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment[J]. Hepatology, 2017, 65( 5): 1438- 1450. DOI: 10.1002/hep.29009. |
| [9] |
CHANG XJ, LV CH, WANG BQ, et al. The utility of P-I-R classification in predicting the on-treatment histological and clinical outcomes of patients with hepatitis B and advanced liver fibrosis[J]. Hepatology, 2024, 79( 2): 425- 437. DOI: 10.1097/HEP.0000000000000563. |
| [10] |
WANG BQ, ZHOU JL, WU XN, et al. Carvedilol plus NUC for patients with HBV-compensated cirrhosis under virological suppression: A randomized open-label trial[J]. Am J Gastroenterol, 2024, 119( 4): 700- 711. DOI: 10.14309/ajg.0000000000002569. |
| [11] |
de FRANCHIS R, BOSCH J, GARCIA-TSAO G, et al. Baveno VII- Renewing consensus in portal hypertension[J]. J Hepatol, 2022, 76( 4): 959- 974. DOI: 10.1016/j.jhep.2021.12.022. |
| [12] |
SUN YM, CHEN W, CHEN SY, et al. Regression of liver fibrosis in patients on hepatitis B therapy is associated with decreased liver-related events[J]. Clin Gastroenterol Hepatol, 2024, 22( 3): 591- 601. e 3. DOI: 10.1016/j.cgh.2023.11.017. |
| [13] |
WANG Q, ZHAO H, DENG Y, et al. Validation of Baveno VII criteria for recompensation in entecavir-treated patients with hepatitis B-related decompensated cirrhosis[J]. J Hepatol, 2022, 77( 6): 1564- 1572. DOI: 10.1016/j.jhep.2022.07.037. |
| [14] |
HE ZY, WANG BQ, WU XN, et al. Recompensation in treatment-naïve HBV-related decompensated cirrhosis: A 5-year multi-center observational study comparing patients with ascites and bleeding[J]. Hepatol Int, 2023, 17( 6): 1368- 1377. DOI: 10.1007/s12072-023-10579-w. |
| [15] |
KONG YY, SUN YM, ZHOU JL, et al. Early steep decline of liver stiffness predicts histological reversal of fibrosis in chronic hepatitis B patients treated with entecavir[J]. J Viral Hepat, 2019, 26( 5): 576- 585. DOI: 10.1111/jvh.13058. |
| [16] |
WU SS, KONG YY, PIAO HX, et al. On-treatment changes of liver stiffness at week 26 could predict 2-year clinical outcomes in HBV-related compensated cirrhosis[J]. Liver Int, 2018, 38( 6): 1045- 1054. DOI: 10.1111/liv.13623. |
| [17] |
WEN XJ, WU XN, SUN YM, et al. Long-term antiviral therapy is associated with changes in the profile of transcriptionally active HBV integration in the livers of patients with CHB[J]. J Med Virol, 2024, 96( 6): e29606. DOI: 10.1002/jmv.29606. |
| [18] |
HAN BF, ZHENG RS, ZENG HM, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4( 1): 47- 53. DOI: 10.1016/j.jncc.2024.01.006. |
| [19] |
QU CF, CHEN TY, FAN CS, et al. Efficacy of neonatal HBV vaccination on liver cancer and other liver diseases over 30-year follow-up of the Qidong hepatitis B intervention study: A cluster randomized controlled trial[J]. PLoS Med, 2014, 11( 12): e1001774. DOI: 10.1371/journal.pmed.1001774. |
| [20] |
Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B(version 2022)[J]. Chin J Infec Dis, 2023, 41( 1): 3- 28. DOI: 10.3760/cma.j.cn311365-20230220-00050. |
| [21] |
WANG Y, WANG M, ZHANG GH, et al. Control of chronic hepatitis B in China: Perspective of diagnosis and treatment[J]. China CDC Wkly, 2020, 2( 31): 596- 600. DOI: 10.46234/ccdcw2020.159. |
| [22] |
TANG M, HE JJ, CHEN MX, et al.“4+7” city drug volume-based purchasing and using pilot program in China and its impact[J]. Drug Discov Ther, 2019, 13( 6): 365- 369. DOI: 10.5582/DDT.2019.01093. |
| [23] |
SU S, WONG WC, ZOU ZR, et al. Cost-effectiveness of universal screening for chronic hepatitis B virus infection in China: An economic evaluation[J]. Lancet Glob Health, 2022, 10( 2): e278- e287. DOI: 10.1016/S2214-109X(21)00517-9. |
| [24] |
Society of Prevention and Control of Infectious Diseases of Chinese Preventive Medicine Association; Working Committee of Promoting the Elimination of Viral Hepatitis of Chinese Preventive Medicine Association. Expert recommendations on screening, testing and management for hepatitis B virus infection in adults[J]. J Clin Hepatol, 2024, 40( 8): 1543- 1550. DOI: 10.12449/JCH240807. 中华预防医学会感染性疾病防控分会, 中华预防医学会促进消除病毒性肝炎工作委员会. 成人乙型肝炎病毒感染筛查、检测及管理专家建议[J]. 临床肝胆病杂志, 2024, 40( 8): 1543- 1550. DOI: 10.12449/JCH240807. |
| [25] |
Working Committee of Promoting the Elimination of Viral Hepatitis of Chinese Preventive Medicine Association; Society of Prevention and Control of Infectious Diseases of Chinese Preventive Medicine Association. Expert recommendations on hepatitis B vaccination in adults[J]. J Clin Hepatol, 2024, 40( 8): 1551- 1556. DOI: 10.12449/JCH240808. 中华预防医学会促进消除病毒性肝炎工作委员会, 中华预防医学会感染性疾病防控分会. 成人乙型肝炎疫苗接种专家建议[J]. 临床肝胆病杂志, 2024, 40( 8): 1551- 1556. DOI: 10.12449/JCH240808. |
| [26] |
WANG BQ, SHAN S, KONG YY, et al. Comparison of the population covered by the 2024 version of the WHO’s hepatitis B prevention and treatment guidelines and the Chinese antiviral treatment guidelines[J]. Chin J Hepatol, 2024, 32( 6): 525- 531. DOI: 10.3760/cma.j.cn501113-20240421-00218. |
| [27] |
WONG GL. Updated guidelines for the prevention and management of chronic hepatitis B-World Health Organization 2024 compared with China 2022 HBV guidelines[J]. J Viral Hepat, 2024, 31( Suppl 2): 13- 22. DOI: 10.1111/jvh.14032. |
| [28] |
ZHANG SH, WANG C, LIU B, et al. Cost-effectiveness of expanded antiviral treatment for chronic hepatitis B virus infection in China: An economic evaluation[J]. Lancet Reg Health West Pac, 2023, 35: 100738. DOI: 10.1016/j.lanwpc.2023.100738. |
| [29] |
YANG JD, HAINAUT P, GORES GJ, et al. A global view of hepatocellular carcinoma: Trends, risk, prevention and management[J]. Nat Rev Gastroenterol Hepatol, 2019, 16( 10): 589- 604. DOI: 10.1038/s41575-019-0186-y. |
| [30] |
ZENG HM, CAO MM, XIA CF, et al. Performance and effectiveness of hepatocellular carcinoma screening in individuals with HBsAg seropositivity in China: A multicenter prospective study[J]. Nat Cancer, 2023, 4( 9): 1382- 1394. DOI: 10.1038/s43018-023-00618-8. |
DownLoad: